Zanidatamab is a humanized bispecific IgG1 monoclonal antibody targeting two non-overlapping epitopes of HER2 (ECD2 and ECD4), with immunomodulating and antineoplastic activities. It has shown anti-tumor activity across various solid tumors with HER2 expression or amplification. M.W 148.28 kDa